疗效和安全性-话题@MedSci

#疗效和安全性#

431篇内容 | 4473人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2177737, encodeId=5abf21e773700, content=<a href='/topic/show?id=c0ae9405422' target=_blank style='color:#2F92EE;'>#过敏性鼻炎#</a> <a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a> <a href='/topic/show?id=be1a109333a8' target=_blank style='color:#2F92EE;'>#皮下免疫疗法#</a>, objectTitle=Otolaryngol Head Neck Surg：皮下免疫疗法在单敏和多敏过敏性鼻炎儿童中的长期疗效和安全性如何？, objectType=article, longId=807214, objectId=e4ef80e214f2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20231228/1703733503584_1935437.jpg, objectUrl=/article/show_article.do?id=e4ef80e214f2, replyNumber=0, likeNumber=100, createdTime=2023-12-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e4ef80e214f2, moduleTitle=Otolaryngol Head Neck Surg：皮下免疫疗法在单敏和多敏过敏性鼻炎儿童中的长期疗效和安全性如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4ef80e214f2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1721220, encodeId=8b631e212208d, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Neurology：难治性局灶性癫痫患者辅助性塞诺巴胺的长期疗效和安全性研究, objectType=article, longId=738700, objectId=3adfe3870050, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3adfe3870050, replyNumber=0, likeNumber=124, createdTime=2023-03-25, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3adfe3870050, moduleTitle=Neurology：难治性局灶性癫痫患者辅助性塞诺巴胺的长期疗效和安全性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3adfe3870050)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721199, encodeId=40801e21199d0, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Clin Oncol：信迪利单抗联合安罗替尼作为二线或后线治疗PD-L1阳性复发或转移(R/M) 宫颈癌的疗效和安全性, objectType=article, longId=728373, objectId=4ee9e283734e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ee9e283734e, replyNumber=0, likeNumber=114, createdTime=2023-03-19, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ee9e283734e, moduleTitle=J Clin Oncol：信迪利单抗联合安罗替尼作为二线或后线治疗PD-L1阳性复发或转移(R/M) 宫颈癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ee9e283734e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721203, encodeId=ae471e212037a, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lancet Oncol：每周用药的剂量密集性化疗在卵巢癌中的疗效和安全性, objectType=article, longId=729044, objectId=5f9ae2904443, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f9ae2904443, replyNumber=0, likeNumber=125, createdTime=2022-11-13, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f9ae2904443, moduleTitle=Lancet Oncol：每周用药的剂量密集性化疗在卵巢癌中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f9ae2904443)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721187, encodeId=28a61e2118757, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=JAMA Cardiol：耄耋之年房颤患者服用小剂量依度沙班的疗效和安全性, objectType=article, longId=724944, objectId=6098e24944ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6098e24944ec, replyNumber=0, likeNumber=108, createdTime=2022-08-24, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6098e24944ec, moduleTitle=JAMA Cardiol：耄耋之年房颤患者服用小剂量依度沙班的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6098e24944ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721212, encodeId=53391e21212bc, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Cosmet Dermatol：微针治疗黄褐斑后外用氨甲环酸与维生素c的疗效和安全性比较, objectType=article, longId=734089, objectId=bd9be3408978, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd9be3408978, replyNumber=0, likeNumber=123, createdTime=2022-10-14, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd9be3408978, moduleTitle=J Cosmet Dermatol：微针治疗黄褐斑后外用氨甲环酸与维生素c的疗效和安全性比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd9be3408978)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721192, encodeId=1e031e2119224, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Genet Med：恩格列净治疗Ib型糖原储存病的疗效和安全性, objectType=article, longId=726340, objectId=194ce2634005, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=194ce2634005, replyNumber=0, likeNumber=116, createdTime=2023-03-14, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=194ce2634005, moduleTitle=Genet Med：恩格列净治疗Ib型糖原储存病的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=194ce2634005)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721196, encodeId=3c641e2119676, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=JCO：ACHIEVE研究最终结果：III期结肠癌奥沙利铂为基础化疗辅助治疗3个月对比6个月的疗效和安全性, objectType=article, longId=727505, objectId=e820e275056e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e820e275056e, replyNumber=0, likeNumber=99, createdTime=2022-09-22, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e820e275056e, moduleTitle=JCO：ACHIEVE研究最终结果：III期结肠癌奥沙利铂为基础化疗辅助治疗3个月对比6个月的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e820e275056e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721177, encodeId=c71e1e21177d6, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=ARD：根据SLE患者I型干扰素基因特征和临床亚组分析Anifrolumab疗效和安全性：两项III期试验汇总数据的事后分析, objectType=article, longId=301850, objectId=439030185039, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=439030185039, replyNumber=0, likeNumber=131, createdTime=2022-04-12, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=439030185039, moduleTitle=ARD：根据SLE患者I型干扰素基因特征和临床亚组分析Anifrolumab疗效和安全性：两项III期试验汇总数据的事后分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=439030185039)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721217, encodeId=d7561e2121700, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Immunol Res：Risankizumab与Ustekinumab治疗银屑病疗效和安全性比较, objectType=article, longId=737625, objectId=1396e376252d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1396e376252d, replyNumber=0, likeNumber=121, createdTime=2023-08-06, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1396e376252d, moduleTitle=J Immunol Res：Risankizumab与Ustekinumab治疗银屑病疗效和安全性比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1396e376252d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721168, encodeId=245f1e2116882, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Ther Adv Med Oncol：依维莫司联合顺铂治疗晚期肺外神经内分泌癌(EP-NEC)的疗效和安全性, objectType=article, longId=300077, objectId=1a413000e765, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a413000e765, replyNumber=0, likeNumber=107, createdTime=2022-04-11, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a413000e765, moduleTitle=Ther Adv Med Oncol：依维莫司联合顺铂治疗晚期肺外神经内分泌癌(EP-NEC)的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a413000e765)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721198, encodeId=0eb51e2119883, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=2022 ASCO：一种新型抗 PD-1 抗体Serplulimab，化疗疗效和安全性研究的3期研究, objectType=article, longId=728406, objectId=362fe28406f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=362fe28406f5, replyNumber=0, likeNumber=115, createdTime=2023-01-01, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=362fe28406f5, moduleTitle=2022 ASCO：一种新型抗 PD-1 抗体Serplulimab，化疗疗效和安全性研究的3期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=362fe28406f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721183, encodeId=686d1e211835b, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Clin Oncol：索拉非尼联合标准化疗治疗FLT3/ITD+急性髓系白血病患儿的疗效和安全性, objectType=article, longId=724175, objectId=74d6e2417552, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74d6e2417552, replyNumber=0, likeNumber=104, createdTime=2022-12-11, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74d6e2417552, moduleTitle=J Clin Oncol：索拉非尼联合标准化疗治疗FLT3/ITD+急性髓系白血病患儿的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74d6e2417552)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721172, encodeId=f6ef1e2117261, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=JEADV：布达鲁（brodalumab）单抗治疗中重度斑块型银屑病的远期疗效和安全性, objectType=article, longId=301181, objectId=285330118105, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=285330118105, replyNumber=0, likeNumber=120, createdTime=2022-11-16, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=285330118105, moduleTitle=JEADV：布达鲁（brodalumab）单抗治疗中重度斑块型银屑病的远期疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=285330118105)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721209, encodeId=d00c1e2120930, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Clin Periodontol：自体牙根在垂直和水平牙槽脊联合增高术和分段种植中的疗效和安全性相当, objectType=article, longId=731078, objectId=7386e310787e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7386e310787e, replyNumber=0, likeNumber=104, createdTime=2023-06-01, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7386e310787e, moduleTitle=J Clin Periodontol：自体牙根在垂直和水平牙槽脊联合增高术和分段种植中的疗效和安全性相当, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7386e310787e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721171, encodeId=26cb1e21171f0, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=JAMA Dermatol:乌帕替尼（Upadacitinib）治疗中重度特应性皮炎的疗效和安全性, objectType=article, longId=301032, objectId=aa2b30103219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa2b30103219, replyNumber=0, likeNumber=124, createdTime=2023-01-17, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa2b30103219, moduleTitle=JAMA Dermatol:乌帕替尼（Upadacitinib）治疗中重度特应性皮炎的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa2b30103219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721206, encodeId=459d1e212067e, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Thromb Haemost：艾多沙班、利伐沙班和阿哌沙班在静脉血栓栓塞患者中的疗效和安全性比较, objectType=article, longId=730707, objectId=45e3e3070798, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45e3e3070798, replyNumber=0, likeNumber=106, createdTime=2022-10-03, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45e3e3070798, moduleTitle=J Thromb Haemost：艾多沙班、利伐沙班和阿哌沙班在静脉血栓栓塞患者中的疗效和安全性比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45e3e3070798)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721189, encodeId=99051e211898b, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Clin Oncol：Durvalumab±Oleclumab/Monalizumab巩固治疗3期非小细胞肺癌的疗效和安全性, objectType=article, longId=724969, objectId=492be249698c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=492be249698c, replyNumber=0, likeNumber=123, createdTime=2022-08-14, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=492be249698c, moduleTitle=J Clin Oncol：Durvalumab±Oleclumab/Monalizumab巩固治疗3期非小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=492be249698c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721215, encodeId=230a1e2121533, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Front Med：5%米诺地尔单独使用、米诺地尔联合螺内酯、米诺地尔联合微针治疗女性型脱发的疗效和安全性, objectType=article, longId=736079, objectId=2865e36079ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2865e36079ea, replyNumber=0, likeNumber=115, createdTime=2023-04-29, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2865e36079ea, moduleTitle=Front Med：5%米诺地尔单独使用、米诺地尔联合螺内酯、米诺地尔联合微针治疗女性型脱发的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2865e36079ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721166, encodeId=2f261e21166f0, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Target Oncol:真实世界评估阿比特龙+泼尼松或泼尼松龙(AAP)一线或二线治疗转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, objectType=article, longId=299289, objectId=97bb29928916, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97bb29928916, replyNumber=0, likeNumber=99, createdTime=2022-12-15, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97bb29928916, moduleTitle=Target Oncol:真实世界评估阿比特龙+泼尼松或泼尼松龙(AAP)一线或二线治疗转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97bb29928916)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

疗效和安全性

2020-05-29

梅斯管理员

#过敏性鼻炎# #疗效和安全性# #皮下免疫疗法#

Otolaryngol Head Neck Surg：皮下免疫疗法在单敏和多敏过敏性鼻炎儿童中的长期疗效和安全性如何？

2023-12-28发表于上海

经常头晕

#疗效和安全性#

Neurology：难治性局灶性癫痫患者辅助性塞诺巴胺的长期疗效和安全性研究

2023-03-25

经常头晕

#疗效和安全性#

J Clin Oncol：信迪利单抗联合安罗替尼作为二线或后线治疗PD-L1阳性复发或转移(R/M) 宫颈癌的疗效和安全性

2023-03-19

经常头晕

#疗效和安全性#

Lancet Oncol：每周用药的剂量密集性化疗在卵巢癌中的疗效和安全性

2022-11-13

经常头晕

#疗效和安全性#

JAMA Cardiol：耄耋之年房颤患者服用小剂量依度沙班的疗效和安全性

2022-08-24

经常头晕

#疗效和安全性#

J Cosmet Dermatol：微针治疗黄褐斑后外用氨甲环酸与维生素c的疗效和安全性比较

2022-10-14

经常头晕

#疗效和安全性#

Genet Med：恩格列净治疗Ib型糖原储存病的疗效和安全性

2023-03-14

经常头晕

#疗效和安全性#

JCO：ACHIEVE研究最终结果：III期结肠癌奥沙利铂为基础化疗辅助治疗3个月对比6个月的疗效和安全性

2022-09-22

经常头晕

#疗效和安全性#

ARD：根据SLE患者I型干扰素基因特征和临床亚组分析Anifrolumab疗效和安全性：两项III期试验汇总数据的事后分析

2022-04-12

经常头晕

#疗效和安全性#

J Immunol Res：Risankizumab与Ustekinumab治疗银屑病疗效和安全性比较

2023-08-06

经常头晕

#疗效和安全性#

Ther Adv Med Oncol：依维莫司联合顺铂治疗晚期肺外神经内分泌癌(EP-NEC)的疗效和安全性

2022-04-11

经常头晕

#疗效和安全性#

2022 ASCO：一种新型抗 PD-1 抗体Serplulimab，化疗疗效和安全性研究的3期研究

2023-01-01

经常头晕

#疗效和安全性#

J Clin Oncol：索拉非尼联合标准化疗治疗FLT3/ITD+急性髓系白血病患儿的疗效和安全性

2022-12-11

经常头晕

#疗效和安全性#

JEADV：布达鲁（brodalumab）单抗治疗中重度斑块型银屑病的远期疗效和安全性

2022-11-16

经常头晕

#疗效和安全性#

J Clin Periodontol：自体牙根在垂直和水平牙槽脊联合增高术和分段种植中的疗效和安全性相当

2023-06-01

经常头晕

#疗效和安全性#

JAMA Dermatol:乌帕替尼（Upadacitinib）治疗中重度特应性皮炎的疗效和安全性

2023-01-17

经常头晕

#疗效和安全性#

J Thromb Haemost：艾多沙班、利伐沙班和阿哌沙班在静脉血栓栓塞患者中的疗效和安全性比较

2022-10-03

经常头晕

#疗效和安全性#

J Clin Oncol：Durvalumab±Oleclumab/Monalizumab巩固治疗3期非小细胞肺癌的疗效和安全性

2022-08-14

经常头晕

#疗效和安全性#

Front Med：5%米诺地尔单独使用、米诺地尔联合螺内酯、米诺地尔联合微针治疗女性型脱发的疗效和安全性

2023-04-29

经常头晕

#疗效和安全性#

Target Oncol:真实世界评估阿比特龙+泼尼松或泼尼松龙(AAP)一线或二线治疗转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性

2022-12-15